Dolutegravir Sodium, Abacavir Sulfate and Lamivudine

Janssen and ViiV Healthcare have reported positive phase III trial results for their once-monthly injectable HIV treatment, combining cabotegravir and Edurant. This innovative regimen could significantly reduce the treatment burden from daily pills to just 12 injections per year, with comparable efficacy to current oral therapies. The findings, presented at the Conference on Retroviruses and Opportunistic Infections, highlight a potential paradigm shift in HIV treatment.

The MIROCALS trial testing low-dose interleukin-2 (IL-2) for motor neurone disease (MND) failed to meet its primary endpoint for the overall population, with results published in The Lancet on May 9, 2025.